Matching articles for "Restoril"
Issue 1667 · January 9, 2023
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)

View the Expanded Table: Some Oral Drugs for Chronic Insomnia

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):e6-10 doi:10.58347/tml.2023.1667b
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Issue 1667 · January 9, 2023
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training,…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):1-6 doi:10.58347/tml.2023.1667a
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Issue 1654 · July 11, 2022
Daridorexant (Quviviq) for Insomnia

The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):107-10
The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Issue 1610 · November 2, 2020 Free
In Brief: New Benzodiazepine Warnings

The FDA now requires boxed warnings in the package inserts of benzodiazepines describing the potential for these drugs to be abused and misused and to cause addiction and physical dependence. Benzodiazepine…

Med Lett Drugs Ther. 2020 Nov 2; 62(1610):175
The FDA now requires boxed warnings in the package inserts of benzodiazepines describing the potential for these drugs to be abused and misused and to cause addiction and physical dependence. Benzodiazepine labels have contained a boxed warning about a risk of serious drug interactions with opioids since 2016.
Issue 1601 · June 29, 2020
Lemborexant (Dayvigo) for Insomnia

The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be…

Med Lett Drugs Ther. 2020 Jun 29; 62(1601):97-100
The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be approved for this indication; suvorexant ( Belsomra ) was the first.
Issue 1562 · December 17, 2018
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):201-5
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.
Issue 1562 · December 17, 2018
Expanded Table: Some Oral Hypnotics for Insomnia (online only)

View the Expanded Table: Some Oral Hypnotics for Insomnia

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):e209-13
View the Expanded Table: Some Oral Hypnotics for Insomnia
Issue 1472 · July 6, 2015
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed…

Med Lett Drugs Ther. 2015 Jul 6; 57(1472):95-8
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed here, are also used. Pharmacologic treatment and behavioral therapy are often combined.
Issue 1463 · March 2, 2015
Suvorexant (Belsomra) for Insomnia

The FDA has approved suvorexant ( Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.

Med Lett Drugs Ther. 2015 Mar 2; 57(1463):29-31
The FDA has approved suvorexant ( Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Issue 119 · July 1, 2012
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.

Treat Guidel Med Lett. 2012 Jul; 10(119):57-60
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.
Issue 79 · March 1, 2009
Drugs for Insomnia

The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.

Treat Guidel Med Lett. 2009 Mar; 7(79):23-6
The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.
Issue 42 · February 1, 2006
Drugs for Insomnia

Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than…

Treat Guidel Med Lett. 2006 Feb; 4(42):5-10
Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than treatment with drugs. Hypnotic drugs are generally FDA-approved only for short-term use, but in practice they often are taken much longer.
Issue 1223 · December 5, 2005
Ambien CR for Insomnia

Zolpidem ( Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has…

Med Lett Drugs Ther. 2005 Dec 5; 47(1223):97-8
Zolpidem ( Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has received FDA approval to market an extended-release formulation of the drug, Ambien CR . The pharmacological rationale for doing so is that short-acting hypnotics like zolpidem are more effective at inducing sleep than they are at maintaining it.
Issue 1203 · February 28, 2005
Eszopiclone (Lunesta), a New Hypnotic

Eszopiclone ( Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone ( Imovane , and others in Canada), which has been…

Med Lett Drugs Ther. 2005 Feb 28; 47(1203):17-9
Eszopiclone ( Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone ( Imovane , and others in Canada), which has been available in other countries for almost 20 years. Unlike similar drugs such as zolpidem ( Ambien ) or zaleplon ( Sonata ), Lunesta is not being restricted in its labeling to short-term use. Like other hypnotics, eszopiclone is a schedule IV drug.
Issue 1084 · August 7, 2000
Hypnotic Drugs

Superseded by Drugs of Choice Handbook Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be…

Med Lett Drugs Ther. 2000 Aug 7; 42(1084):71-2
Superseded by Drugs of Choice Handbook Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective than drugs.
Issue 1063 · October 8, 1999
Zaleplon for Insomnia

Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.

Med Lett Drugs Ther. 1999 Oct 8; 41(1063):93-4
Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.
Issue 978 · July 5, 1996
Hypnotic Drugs

Superseded by Drugs of Choice Handbook Insomnia is a commom complaint, particularly among the elderly. Many drugs are approved by the US Food and Drug Administration (FDA) for treatment of insomnia, including…

Med Lett Drugs Ther. 1996 Jul 5; 38(978):59-61
Superseded by Drugs of Choice Handbook Insomnia is a commom complaint, particularly among the elderly. Many drugs are approved by the US Food and Drug Administration (FDA) for treatment of insomnia, including five benzodiazepines and zolpidem ( Ambien ), a non-benzodiazepine that binds to benzodiazepine receptors in the brain. Some drugs marketed for other indications, such as antihistamines, antidepressants and antipsychotics, are also used as hypnotics. For many patients, nonpharmacological treatment of insomnia may be more effective than drugs, especially in the long term (CM Morin et al, Am J Psychiatry, 151:1172, 1994).
Issue 854 · October 4, 1991
Estazolam - A New Benzodiazepine Hypnotic

Estazolam ( ProSom - Abbott), a triazolobenzodiazepine derivative similar in structure to alprazolam ( Xanax ) and triazolam ( Halcion ), was recently marketed in the USA for treatment of insomnia.

Med Lett Drugs Ther. 1991 Oct 4; 33(854):91-2
Estazolam ( ProSom - Abbott), a triazolobenzodiazepine derivative similar in structure to alprazolam ( Xanax ) and triazolam ( Halcion ), was recently marketed in the USA for treatment of insomnia.
Issue 816 · April 20, 1990
Quazepam: A New Hypnotic

Quazepam ( Doral - Baker Cummins, Wallace) is a trifluoroethyl benzodiazepine made by Schering and approved in 1985 by the US Food and Drug Administration for treatment of insomnia. Like other benzodiazepines,…

Med Lett Drugs Ther. 1990 Apr 20; 32(816):39-40
Quazepam ( Doral - Baker Cummins, Wallace) is a trifluoroethyl benzodiazepine made by Schering and approved in 1985 by the US Food and Drug Administration for treatment of insomnia. Like other benzodiazepines, it is a Schedule IV controlled substance.Quazepam ( Doral - Baker Cummins, Wallace) is a trifluoroethyl benzodiazepine made by Schering and approved in 1985 by the US Food and Drug Administration for treatment of insomnia. Like other benzodiazepines, it is a Schedule IV controlled substance.
Issue 787 · March 10, 1989
Oral Hypnotic Drugs

Three benzodiazepines and 16 other compounds are marketed in the USA for treatment of insomnia. Many authorities believe that insomnia is overdiagnosed and overtreated (MK Erman, ed, Sleep Disorders, Psychiatr…

Med Lett Drugs Ther. 1989 Mar 10; 31(787):23-4
Three benzodiazepines and 16 other compounds are marketed in the USA for treatment of insomnia. Many authorities believe that insomnia is overdiagnosed and overtreated (MK Erman, ed, Sleep Disorders, Psychiatr Clin North Am, Volume 10, Dec 1987).
Issue 760 · February 26, 1988
Choice of Benzodiazepines

Since The Medical Letter last reviewed the choice of benzodiazepines (Volume 23, page 41, 1981), several new drugs have been marketed and some old ones are now available generically. Most of the…

Med Lett Drugs Ther. 1988 Feb 26; 30(760):26-8
Since The Medical Letter last reviewed the choice of benzodiazepines (Volume 23, page 41, 1981), several new drugs have been marketed and some old ones are now available generically. Most of the benzodiazepines available for oral use in the USA are listed in the table on page 28.